Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (178)	11/20/2006 5:17:16 PM
From: david nordic	Read Replies (1) \| Respond to of 507

11.20.06 nktr: IMPROVING VISIBILITY; GPS ADOPTING; SETS STAGE FOR DTC; EXUBERA SUPERBOWL WOULD BE TOUCHDOWN Folks, the Exubera train is finally leaving the station. Pfizer has opened up the GP playbook and now appears to be implementing its second marketing phase targeting GPs and utilizing positive experiences in symposia to drive GP adoption. Our individual experience confirmed this last week. Following an annual check up with a GP who had been an early adopter of Lantus a few years ago, we were pleasantly surprised that not only has this internist heard of Exubera, he has ten patients taking Exubera and said, 'They all love it'. Dr. Tyroler's not an endocrinologist, but has seen many diabetic patients. Most were switched from injectable insulin: three Type I's who still use Lantus (long acting once a day), and the rest Type 2's who have stopped injectable insulin for Exubera and in 3 cases, had failed oral therapy, but were badly out of control. 'Nothing was working...but Exubera has in just one month.' This physician plans to speak at a regional symposia Pfizer is sponsoring the week after Thanksgiving that will be attended by other GPs. With this encouraging development which appears ahead of Pfizer's recent guidance of GP (or second marketing phase) for January, we managed to contact several other GPs who have recently prescribed Exubera in major regions - the Bay Area, Connecticut, New Jersey, and Texas. The enthusiasm was largely the same as here in Fairfax. While admittedly anecdotal, at a minimum we can infer the following that we view as positive for NKTR stock which has enjoyed a 15% rise in the last few weeks during a period where healthcare stocks, particularly drug stocks, have underperformed post the elections.